Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sagimet Biosciences Inc. filings document a clinical-stage biopharmaceutical issuer with Series A common stock listed on the Nasdaq Global Market and emerging growth company status. Recent 8-K reports cover financial results, preliminary financial information, Regulation FD investor presentations, a material underwriting agreement and related capital-structure disclosures, and executive leadership changes.
The company’s proxy materials describe annual meeting voting matters, stockholder procedures, board-related items, and governance proposals. Its disclosures also track use-of-proceeds language, clinical-development updates for FASN inhibitor programs, and public-company reporting matters.
Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek received a grant of stock options as part of her compensation. She was awarded 100,000 stock options, each giving the right to buy one share of Series A common stock at an exercise price of $7.27 per share. These options expire on May 27, 2036. According to the terms, the shares underlying this option will vest in 48 equal monthly installments beginning after May 28, 2026, contingent on her continued service, and her reported derivative holdings after this grant total 100,000 options.
Sagimet Biosciences Inc. reported that President & CEO David Happel received a grant of stock options covering 300,000 shares of Series A common stock. The options have an exercise price of $7.27 per share and were awarded at no cost to him.
These options vest in forty-eight equal monthly installments starting on May 28, 2026, contingent on his continued service. After this grant, he holds options on 300,000 shares according to the filing. The transaction reflects equity-based compensation rather than an open-market purchase or sale.
Sagimet Biosciences reported that Chief Medical Officer Andreas Grauer received a grant of stock options covering 264,759 shares of Series A common stock. The options have an exercise price of $6.44 per share and expire on April 19, 2036.
According to the vesting terms, 25% of the underlying shares vest on April 20, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on continued service. Following this grant, Grauer holds derivative rights over 264,759 shares through this option award.
Sagimet Biosciences Inc. filed a Form 3 insider report for Andreas Grauer, who is identified as the company’s Chief Medical Officer. The filing does not list any securities transactions or derivative positions, and no share holdings are detailed in the provided data.
Sagimet Biosciences reported first quarter 2026 results alongside major financing and pipeline updates. The company completed a $175 million equity financing in April 2026 and now expects its cash, cash equivalents and marketable securities to fund operations through 2028, including data readout from a planned Phase 3 acne trial of denifanstat.
For the quarter ended March 31, 2026, Sagimet reported a net loss of $10.7 million compared with $18.2 million a year earlier, as total operating expenses fell to $11.7 million from $19.9 million. Net loss per share improved to $0.33 from $0.56, with weighted-average shares of about 32.6 million. Cash, cash equivalents and marketable securities were $104.5 million as of March 31, 2026, down modestly from $113.1 million at year-end 2025.
Sagimet Biosciences Inc. reported a net loss of $10.7 million for the quarter ended March 31, 2026, an improvement from $18.2 million a year earlier. The smaller loss was driven by a 54% drop in research and development expense to $7.0 million as Phase 3 MASH work wound down and spending shifted toward acne programs.
General and administrative costs were stable at $4.7 million, while other income declined to $1.1 million due to lower cash balances and yields. Sagimet ended the quarter with $104.5 million in cash, cash equivalents and marketable securities and then raised about $175.0 million in an April 2026 underwritten offering, which it expects to fund operations for at least 12 months.
The company continues to advance FASN inhibitor programs: denifanstat, which met Phase 3 acne endpoints in China through its partner Ascletis, is planned to enter a U.S. Phase 3 acne trial after an IND filing in mid-2026, and TVB-3567 is in a Phase 1 acne study. Further MASH development will pause until non-dilutive financing is secured.
Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share. The Company expects to receive $164.5 million in net proceeds after underwriting discounts and commissions.
The Company plans to use the proceeds, together with existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, advance TVB-3567 through Phase 2 topline results, move a topical FASN inhibitor to IND submission, and for general corporate purposes including additional clinical development, working capital and operating expenses.
Sagimet Biosciences is offering 29,166,700 shares of Series A common stock at $6.00 per share, for an aggregate offering price of $175,000,200 via a shelf prospectus supplement. The underwriters’ discount is $0.36 per share, providing estimated net proceeds to the company of approximately $163.9 million. The shares are expected to be delivered on or about April 28, 2026. Proceeds are intended to fund a Phase 3 acne trial for denifanstat, advance TVB-3567 through Phase 2 topline results, support a topical FASN program to IND, and for general corporate purposes. The supplement discloses a preliminary cash balance of approximately $104.5 million as of March 31, 2026 (unaudited).
Sagimet Biosciences Inc. furnished an updated investor slide presentation as an exhibit to a current report. The presentation, dated April 27, 2026, is attached as Exhibit 99.1 and will be used in meetings with investors.
The materials are provided under Item 7.01 as information that is being furnished, not deemed filed under the Exchange Act, and are only incorporated by reference in other filings if specifically referenced.
Sagimet Biosciences Inc. furnished an updated investor slide presentation as an exhibit to a current report. The presentation, dated April 27, 2026, is attached as Exhibit 99.1 and will be used in meetings with investors.
The materials are provided under Item 7.01 as information that is being furnished, not deemed filed under the Exchange Act, and are only incorporated by reference in other filings if specifically referenced.
Sagimet Biosciences Inc. furnished preliminary financial data and strategic updates. The company estimates unaudited cash, cash equivalents and marketable securities of approximately $104.5 million as of March 31, 2026, noting this figure may change after normal closing procedures and review.
Sagimet plans a U.S. Phase 3 clinical trial of its FASN inhibitor denifanstat for moderate to severe acne, expected to start in the second half of 2026, following positive Phase 3 safety data from its license partner in China. A first-in-human Phase 1 trial of FASN inhibitor TVB-3567 is ongoing.
The company is prioritizing its dermatology franchise in capital allocation and plans to advance its MASH program only if it secures non-dilutive funding. Sagimet will host a virtual KOL event on April 30, 2026 at 2 p.m. ET to discuss denifanstat’s acne development.
Sagimet Biosciences Inc. furnished preliminary financial data and strategic updates. The company estimates unaudited cash, cash equivalents and marketable securities of approximately $104.5 million as of March 31, 2026, noting this figure may change after normal closing procedures and review.
Sagimet plans a U.S. Phase 3 clinical trial of its FASN inhibitor denifanstat for moderate to severe acne, expected to start in the second half of 2026, following positive Phase 3 safety data from its license partner in China. A first-in-human Phase 1 trial of FASN inhibitor TVB-3567 is ongoing.
The company is prioritizing its dermatology franchise in capital allocation and plans to advance its MASH program only if it secures non-dilutive funding. Sagimet will host a virtual KOL event on April 30, 2026 at 2 p.m. ET to discuss denifanstat’s acne development.